
    
      This was a double-blind, randomized, placebo-controlled trial, to be conducted over 10 months
      at five research centers in the USA among 180 healthy, sexually active women, to assess the
      safety and acceptability of dapivirine Gel 4759, 0.05% 2.5 g, and dapivirine Gel 4789, 0.05%
      2.5 g, both vaginal microbicides containing dapivirine, compared to the vaginal HEC-based
      Universal placebo gel, 2.5 g, containing no active ingredient, used once daily for a period
      of 12 weeks.
    
  